Used in the treatment of moderate to severe plaque psoriasis, this antibody targets interleukin-17A, a key cytokine involved in inflammatory pathways. By blocking IL-17A, it reduces skin inflammation and slows the rapid growth of skin cells that cause psoriatic plaques. It is also prescribed for psoriatic arthritis and ankylosing spondylitis, helping to decrease joint pain, swelling, and stiffness. Administered via subcutaneous injection, it offers long-term control of disease symptoms with regular dosing. Its high specificity for IL-17A minimizes broader immune suppression, making it a targeted therapy option for chronic autoimmune conditions.